<!DOCTYPE html>
<html>
<head>
    <title>Ris&#xAD;ing un&#xAD;cer&#xAD;tainty over In&#xAD;done&#xAD;sia&#x2019;s vac&#xAD;cine pro&#xAD;gramme - PressReader</title>
    <meta name="description" content="De&#xAD;lays in roll-out have led to doubts about safety of vac&#xAD;cine can&#xAD;di&#xAD;date in fi&#xAD;nal-stage trial">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20201119/281685437386193" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Ris&#xAD;ing un&#xAD;cer&#xAD;tainty over In&#xAD;done&#xAD;sia&#x2019;s vac&#xAD;cine pro&#xAD;gramme</h1>
    <h2>De&#xAD;lays in roll-out have led to doubts about safety of vac&#xAD;cine can&#xAD;di&#xAD;date in fi&#xAD;nal-stage trial</h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20201119/textview" title="The Straits Times - 2020-11-19"><time>2020-11-19</time></a>
        - <span>THE BIG STORY</span>
        - <span role="byline">Wahyudi So&#xAD;e&#xAD;ri&#xAD;aat&#xAD;madja In&#xAD;done&#xAD;sia Cor&#xAD;re&#xAD;spon&#xAD;dent In Jakarta wahyudis@sph.com.sg</span>
    </section>

    <p>The In­done­sian gov­ern­ment’s flipflop­ping over the tim­ing of a Covid-19 vac­ci­na­tion roll-out has cast doubts that a mass vac­ci­na­tion pro­gramme an­nounced ear­lier will start next month.</p>
    <p>At a marathon par­lia­men­tary hear­ing on Tues­day, sev­eral Mem­bers of Par­lia­ment noted that the de­lays have sparked un­cer­tainty among the public about the safety and ef­fec­tive­ness of the vac­cines be­ing de­vel­oped, with some peo­ple ex­press­ing their re­luc­tance to be vac­ci­nated.</p>
    <p>Pres­i­dent Joko Wi­dodo’s ad­min­is­tra­tion had ear­lier an­nounced that a vac­ci­na­tion pro­gramme will be­gin this month, but last week told Reuters it will be by the end of this year.</p>
    <p>At the hear­ing, Dr Penny K. Luk­ito, head of In­done­sia’s food and drug agency BPOM, ruled out emer­gency-use au­tho­ri­sa­tion next month.</p>
    <p>She told MPs that six months’ worth of trial data need to be an­a­lysed be­fore the in­de­pen­dent agency can is­sue such au­tho­ri­sa­tion.</p>
    <p>In­done­sia’s state drug­maker Bio Farma and the Univer­sity of Pad­jad­jaran are jointly con­duct­ing a phase three clin­i­cal trial of a vac­cine can­di­date, Coron­aVac, which is be­ing de­vel­oped by China’s Si­no­vac Biotech.</p>
    <p>The Straits Times un­der­stands that there has not been a re­port of neg­a­tive ef­fects on vol­un­teers in­volved in the trial, which is be­ing con­ducted in Ban­dung, West Java.</p>
    <p>The vol­un­teers will have their next med­i­cal ex­am­i­na­tion and blood test on Nov 24.</p>
    <p>Dr Penny said Bio Farma is sched­uled to re­lease in Jan­uary data from the phase three clin­i­cal trial, which in­volves more than 1,600 vol­un­teers.</p>
    <p>The in­terim anal­y­sis would serve as a ba­sis for Bio Farma to file for an emer­gency-use ap­proval for the Coron­aVac vac­cine, she added.</p>
    <p>At the same health com­mit­tee hear­ing, Health Min­is­ter Ter­awan Agus Pu­tranto said no clear sched­ule for a mass vac­ci­na­tion pro­gramme can be con­firmed yet.</p>
    <p>Com­mit­tee mem­ber Pu­tih Sari told the min­is­ter: “The gov­ern­ment’s state­ments keep changing and it has caused doubts... If our clin­i­cal tri­als have not been com­pleted, re­frain from mak­ing an­nounce­ments and don’t make prom­ises.”</p>
    <p>An­other com­mit­tee mem­ber, Ms An­gia Ema Rini, said that as a re­sult of the de­lays, many In­done­sians do not have trust in the vac­cine can­di­dates the coun­try is test­ing.</p>
    <p>FI­NAL STAGE</p>
    <p>The phase three trial, the fi­nal stage a vac­cine can­di­date must clear be­fore it is given the goa­head for use, started in Au­gust.</p>
    <p>Dr Penny said that if Coron­aVac trig­gers an an­ti­body re­sponse in at least 50 per cent of the vol­un­teers who were given the vac­cine shots, it would be enough for her agency to is­sue emer­gency-use ap­proval.</p>
    <p>“In nor­mal times, the World Health Or­gan­i­sa­tion says 70 per cent is re­quired. In a pan­demic, 50 per cent suf­fices,” Dr Penny told MPs at the hear­ing.</p>
    <p>State-Owned En­ter­prises Deputy Min­is­ter Budi Gu­nadi Sadikin, who heads the eco­nomic re­cov­ery desk in the gov­ern­ment’s Covid-19 task force, said the vac­ci­na­tion pro­gramme would cover 67 per cent of the pop­u­la­tion aged be­tween 18 and 59, or 107.2 mil­lion peo­ple.</p>
    <p>Dr Penny said there is an op­tion for com­pas­sion­ate-use au­tho­ri­sa­tion, which would al­low the use of the vac­cine in re­stricted groups, such as med­i­cal work­ers.</p>
    <p>Un­like emer­gency-use au­tho­ri­sa­tion, a com­pas­sion­ate-use ap­proval does not re­quire clin­i­cal trial data to be re­viewed by BPOM.</p>
    <p>“On the re­quest of the Health Min­is­ter, BPOM may is­sue com­pas­sion­ate-use au­tho­ri­sa­tion. Other coun­tries do this as well,” Dr Penny said, not­ing that in this case, In­done­sia could start rolling out a vac­ci­na­tion pro­gramme next month.</p>
    <p>When pressed by law­mak­ers on whether the vac­ci­na­tion pro­gramme would be­gin next month, Min­is­ter Ter­awan said: “The sooner the bet­ter, but safety is pri­or­ity.”</p>

    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=dGSRhl2P3%2fpp9vb38ZJH3g%3d%3d" />
        </picture>
        <span role="byline">PHOTO: AGENCE FRANCE-PRESSE</span>
        <p data-role="text">A vol&#xAD;un&#xAD;teer tak&#xAD;ing part in a Covid-19 vac&#xAD;ci&#xAD;na&#xAD;tion drill in Bo&#xAD;gor, West Java. In&#xAD;done&#xAD;sia&#x2019;s state drug&#xAD;maker Bio Farma and the Univer&#xAD;sity of Pad&#xAD;jad&#xAD;jaran are jointly con&#xAD;duct&#xAD;ing a phase three clin&#xAD;i&#xAD;cal trial of a vac&#xAD;cine can&#xAD;di&#xAD;date, Coron&#xAD;aVac, which is be&#xAD;ing de&#xAD;vel&#xAD;oped by China&#x2019;s Si&#xAD;no&#xAD;vac Biotech. The trial, which started in Au&#xAD;gust, in&#xAD;volves more than 1,600 vol&#xAD;un&#xAD;teers.</p>
    </div>
    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=9FByQQFwlxm4hdDhxWVM1g%3d%3d" />
        </picture>
        <span role="byline">PHOTO: AGENCE FRANCE-PRESSE</span>
        <p data-role="text">In&#xAD;done&#xAD;sian Pres&#xAD;i&#xAD;dent Joko Wi&#xAD;dodo&#x2019;s ad&#xAD;min&#xAD;is&#xAD;tra&#xAD;tion had ear&#xAD;lier an&#xAD;nounced that a vac&#xAD;ci&#xAD;na&#xAD;tion pro&#xAD;gramme will be&#xAD;gin this month, but last week told Reuters it will be by the end of this year.</p>
    </div>

</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
